CMAB009 plus irinotecan versus irinotecan‐only as second‐line treatment after fluoropyrimidine and oxaliplatin failure in <i>KRAS</i> wild‐type metastatic colorectal cancer patients: promising findings from a prospective, open‐label, randomized, phase III trial
Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Guoping Sun(Anhui Medical University), Shukui Qin(81th Hospital of PLA), Zhehai Wang(Shandong Tumor Hospital), Yi Luo(Kunming Institute of Botany), Ying Cheng(Jilin Province Tumor Hospital), Feng Bi(Tianjin University of Traditional Chinese Medicine), Yigui Chen(Fujian Medical University), Yan Sun(Peking University), Yuhong Li(Southwest Jiaotong University), Qiang Yao(Southern University of Science and Technology), Liwei Wang(Shanghai Jiao Tong University), Wei Liu(Academy of Military Medical Sciences), Li Bai(Chinese Academy of Medical Sciences & Peking Union Medical College), Jianming Xu(Chinese PLA General Hospital), Yiping Zhang(China National Center for Biotechnology Development), Xiaohua Hu(Cincinnati Children's Hospital Medical Center), Xiaohui He(Chinese Academy of Medical Sciences & Peking Union Medical College), Rongsheng Zheng(First Affiliated Hospital of Bengbu Medical College), Yunpeng Liu(Shenyang Institute of Automation), Jin Li(Shanghai East Hospital)
Cited by 11
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k